Notice of Change to Funds Available, Anticipated Number of Awards, and Contact Information for RFA-FD-13-014 "Development of in vivo Predictive Dissolution Method for Orally Inhaled Drug Products (U01)"

Notice Number: NOT-FD-13-003

Release Date: May 3, 2013

RFA-FD-13-014

Food and Drug Administration (FDA)
Center for Drug Evaluation and Research

The purpose of this Notice is to correct the Funds Available and Anticipated Number of Awards and the contact information in the funding opportunity announcement RFA-FD-13-014.

1. Funds Available: The total funds available for funding opportunity announcement RFA-FD-13-014, entitled Development of in vivo predictive dissolution method for orally inhaled drug products are $600,000. It is anticipated that three awards will be made in the amount of $200,000 (Direct and Indirect Costs) each.

2. Contact Information:

Scientific/Research Contact(s)

Sau L. Lee
Food and Drug Administration
Office of Generic Drugs (OGD)
Telephone: 240-276-8426
Email: sau.lee@fda.hhs.gov

Bhawana Saluja
Food and Drug Administration
Office of Generic Drugs (OGD)
Telephone: 240-276-8465
Email: bhawana.saluja@fda.hhs.gov

Objective Review Contact(s)

Bhawana Saluja
Food and Drug Administration
Office of Generic Drugs (OGD)
Telephone: 240-276-8465
Email: bhawana.saluja@fda.hhs.gov

Please direct all inquiries to:

Gladys Melendez
Grants Management Officer/ Grants Management Specialist
Food and Drug Administration
Telephone: 301-827-7175
Email: gladys.bohler@fda.hhs.gov